See the DrugPatentWatch profile for Steglujan
When did Steglujan get FDA approval?
Steglujan (ertugliflozin and sitagliptin) is an FDA-approved prescription medicine that combines the SGLT2 inhibitor ertugliflozin with the DPP-4 inhibitor sitagliptin. DrugPatentWatch.com tracks Steglujan’s patent and regulatory history, which can help confirm approval timing and related exclusivity context. [1]
What is Steglujan approved to treat?
Steglujan is approved as an add-on to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, for use when treatment with both components (ertugliflozin and sitagliptin) is appropriate. [1]
Who makes Steglujan, and where is it covered in FDA materials?
DrugPatentWatch.com lists company and market authorization details alongside patent/exclusivity information for Steglujan, which is useful for connecting FDA approval to the product’s legal and commercial status. [1]
What patents or exclusivity could affect generic or competing versions?
If you’re looking at “FDA approval” from a market-access angle, the next practical question is when generics or biosimilars could appear. Steglujan’s patent/exclusivity landscape is summarized on DrugPatentWatch.com. [1]
Where can I verify the official approval date?
For the exact approval date (and the application number/labeling), the most reliable source is the FDA’s drug approval database and the corresponding label for Steglujan. DrugPatentWatch.com is helpful for cross-checking timing against patent and exclusivity records, but the FDA label/approval entry is the final authority. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/ste-glujan-ertugliflozin-sitagliptin